Business Description
Reshape Lifesciences Inc
NAICS : 334510
SIC : 3845
ISIN : US76090R2004
Description
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.89 | |||||
| Equity-to-Asset | 0.27 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -161.6 | |||||
| Beneish M-Score | -3.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -80.5 | |||||
| 3-Year EBITDA Growth Rate | 80.2 | |||||
| 3-Year EPS without NRI Growth Rate | 76.7 | |||||
| 3-Year FCF Growth Rate | 73.6 | |||||
| 3-Year Book Growth Rate | 91.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.42 | |||||
| 9-Day RSI | 56.62 | |||||
| 14-Day RSI | 51.69 | |||||
| 6-1 Month Momentum % | -49.74 | |||||
| 12-1 Month Momentum % | -57.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.33 | |||||
| Quick Ratio | 0.6 | |||||
| Cash Ratio | 0.18 | |||||
| Days Inventory | 465.32 | |||||
| Days Sales Outstanding | 104.62 | |||||
| Days Payable | 213.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 59.7 | |||||
| Shareholder Yield % | -0.36 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.19 | |||||
| Operating Margin % | -96.79 | |||||
| Net Margin % | -86.36 | |||||
| FCF Margin % | -75.73 | |||||
| ROE % | -187.93 | |||||
| ROA % | -91.24 | |||||
| ROIC % | -272.19 | |||||
| ROC (Joel Greenblatt) % | -296.21 | |||||
| ROCE % | -200.63 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.32 | |||||
| PB Ratio | 2.73 | |||||
| Price-to-Tangible-Book | 2.73 | |||||
| EV-to-EBIT | -0.44 | |||||
| EV-to-EBITDA | -0.44 | |||||
| EV-to-Revenue | 0.43 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -0.56 | |||||
| Price-to-Net-Current-Asset-Value | 3.34 | |||||
| Earnings Yield (Greenblatt) % | -227.27 | |||||
| FCF Yield % | -151.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RSLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Reshape Lifesciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.183 | ||
| EPS (TTM) ($) | -16.008 | ||
| Beta | 1.56 | ||
| Volatility % | 81.09 | ||
| 14-Day RSI | 51.69 | ||
| 14-Day ATR ($) | 0.569315 | ||
| 20-Day SMA ($) | 5.5635 | ||
| 12-1 Month Momentum % | -57.25 | ||
| 52-Week Range ($) | 4.6 - 34.22 | ||
| Shares Outstanding (Mil) | 0.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Reshape Lifesciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Reshape Lifesciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Reshape Lifesciences Inc Frequently Asked Questions
What is Reshape Lifesciences Inc(RSLS)'s stock price today?
The current price of RSLS is $5.75. The 52 week high of RSLS is $34.22 and 52 week low is $4.60.
When is next earnings date of Reshape Lifesciences Inc(RSLS)?
The next earnings date of Reshape Lifesciences Inc(RSLS) is 2025-02-14 Est..
Does Reshape Lifesciences Inc(RSLS) pay dividends? If so, how much?
Reshape Lifesciences Inc(RSLS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers